REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al; Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
3. Caviglia GP, Rizzetto M. Treatment of hepatitis D: an unmet medical need. Clin Microbiol Infect 2020;26:824-7.
4. Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, et al. A territorywide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. J Infect Dis 2019;219:1924-33.
5. Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol 2020; doi: 10.1016/j.jhep.2020.02.030.
6. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 2019;70:674-83.
7. Maticic M, Mondelli MU. Elimination of viral hepatitis: where do we stand in the year 2020? Clin Microbiol Infect 2020;26:816-7.
8. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol 2016;64:S41-8.
10. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016;36:1239-51.
12. Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018;27:205-12.
13. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-12.
14. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
15. Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93.
16. Yang H, Yuen M, Chan HL, Han K, Chen P, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
17. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
18. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5.
19. Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 2015;63:722-32.
20. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, et al; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
21. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
22. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-8.
23. Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B virus infection and alcohol consumption. World J Gastroenterol 2017;23:2651-9.
24. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, et al. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1261-8.
25. Liu X, Baecker A, Wu M, Zhou JY, Yang J, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population. Int J Cancer 2018;142:1560-7.
26. Kim K, Choi S, Park SM. Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a Korean population-based cohort study. JAMA Oncol 2018;4:737-9.
27. Tan Y, Wei S, Zhang W, Yang J, Yang J, et al. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res 2019;11:705-13.
28. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology 2017;65:828-35.
29. Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat 2018;25:97-104.
30. Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol 2018;16:575-83.e2.
31. Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 2014;39:883-93.
32. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
33. Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis 2012;25:570-7.
34. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327-34.
35. Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, et al. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:517-26.
36. Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol 2014;109:1241-9.
37. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
38. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
39. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014;20:5951-61.
40. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, et al; Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019;71:397-408.
41. Wang H, Swann R, Thomas E, Innes HA, Valerio H, et al. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. J Viral Hepat 2018;25:930-8.
42. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007;146:649-56.
43. Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: a meta-analysis. Medicine (Baltimore) 2016;95:e4311.
44. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, et al; Italian Association of the Study of the Liver Disease (AISF). Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol 2008;103:1966-72.
45. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, et al. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int 2014;34:e144-50.
46. Kim JH, Kim MN, Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int 2015;35:1103-15.
47. Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885-94.
48. Huang R, Jiang N, Yang R, Geng X, Lin J, et al. Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B. Exp Ther Med 2016;11:1673-7.
49. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8.
50. Wong GL, Chan HL, Wong CK, Leung C, Chan CY, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 2014;60:339-45.
51. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6.
52. Jung KS, Kim SU, Song K, Park JY, Kim DY, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology 2015;62:1757-66.
53. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44:765-9.
54. Wang M, Xi D, Ning Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int 2017;11:171-80.
55. Wu S, Kanda T, Nakamoto S, Jiang X, Nakamura M, et al. Cooperative effects of hepatitis B virus and TNF may play important roles in the activation of metabolic pathways through the activation of NF-κB. Int J Mol Med 2016;38:475-81.
56. Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. In: Cai Q, Yuan Z, Lan K, editors. Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. Singapore: Springer; 2017. pp. 11-21.
57. Wang W, Bian H, Li F, Li X, Zhang D, et al. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. Cell Mol Life Sci 2018;75:2627-41.
58. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, et al. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011;54:1177-84.
59. Tian Y, Ou JH. Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma. Virol Sin 2015;30:85-91.
60. Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, et al. HBV core protein enhances cytokine production. Diseases 2015;3:213-20.
61. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
62. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci 2019;20:1358.
63. WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: WHO; 2016.
64. Ward JW, Hinman AR. What is needed to eliminate hepatitis b virus and hepatitis C virus as global health threats. Gastroenterology 2019;156:297-310.
65. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, et al. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010;28:730-6.
66. WHO. Global hepatitis report, 2017. Geneva, Switzerland: WHO; 2017.
67. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
68. Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 2015;61:1154-62.
69. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444-53.
70. Li M, Lv T, Wu S, Wei W, Wu X, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14:105-14.
71. Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology 2020;71:2023-32.
72. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-32.
73. Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 2014;111:1562-71.
74. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
75. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-30.
76. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019;179:633-40.
77. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-94.
78. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012;109:E2165-72.
79. Calvisi DF. Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention? Hepatology 2013;57:848-50.
80. Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013;11:95-101.
81. Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. Cancer 2017;123:1202-11.
82. Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8.
83. Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology 2014;60:1871-8.
84. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, et al. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget 2017;8:43925-33.
85. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
86. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004;164:2349-54.
87. López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, et al; GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011;25:899-904.
88. Tovo CV, Becker SC, Almeida PR, Galperim B, Chaves S. Progression of liver fibrosis in monoinfected patients by hepatitis C virus and coinfected by HCV and human immunodeficiency virus. Arq Gastroenterol 2013;50:19-22.
89. Puoti M, Prestini K, Putzolu V, Zanini B, Baiguera C, et al. HIV/HCV co-infection: natural history. J Biol Regul Homeost Agents 2003;17:144-6.
90. Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, et al; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. Hepatology 2019;70:939-54.
91. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol 2015;28:221-8.
92. Lee LP, Dai CY, Chuang WL, Chang WY, Hou NJ, et al. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007;22:515-7.
93. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7.
94. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98-105.
95. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50:1142-54.
96. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
97. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9.
98. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.
99. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, et al; Brescia HCC Study. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Int J Cancer 1999;81:695-9.
100. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004;39:826-34.
101. Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: a prospective study. J Hepatol 2016;65:543-51.
102. Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci 2016;61:636-45.
103. Huang TS, Lin CL, Lu MJ, Yeh CT, Liang KH, et al. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: a population-based cohort study. J Gastroenterol Hepatol 2017;32:1355-62.
104. Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, et al. NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016;17:803.
105. Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003;52:288-92.
106. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
107. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat 2009;16:492-9.
108. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 2014;20:7089-103.
109. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630-6.
110. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007;13:5180-7.
111. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007;109:2490-6.
112. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005;20:1395-400.
113. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-43.
114. Rao H, Wu E, Fu S, Yang M, Feng B, et al. The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. Aliment Pharmacol Ther 2017;46:731-40.
115. Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013;108:1723-30.
116. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014;146:1249-55.e1.
117. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005;40:148-56.
118. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014;61:S79-90.
120. Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, et al. High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine 2013;62:421-5.
121. Braconi C, Valeri N, Gasparini P, Huang N, Taccioli C, et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res 2010;16:957-66.
122. Zhang Y, Wei W, Cheng N, Wang K, Li B, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012;56:1631-40.
123. Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013;19:7836-45.
124. Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-coding RNAs and hepatitis C virus-induced hepatocellular carcinoma. Viruses 2018;10:591.
125. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996;70:4438-43.
126. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. Biology (Basel) 2013;2:304-16.
127. WHO. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016.2018; Available from: http://origin.who.int/healthinfo/global_burden_disease/estimates/en/. [Last accessed on 22 Jul 2017].
128. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res 2014;110:79-93.
129. European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461-511.
130. Cooke GS, Andrieux-meyer I, Applegate TL, Atun R, Burry JR, et al. Accelerating the elimination of viral hepatitis: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol 2019;4:135-84.
131. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
132. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.
133. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2019;69:487-97.
134. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al; Rete Sicilia Selezione Terapia-HCV (RESIST-HCV). Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-21.e4.
135. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
136. Colombo M, Boccaccio V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat Rev Gastroenterol Hepatol 2018;15:392-3.
137. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
138. Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, et al. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol 2020; doi: 10.1016/j.jhep.2020.03.030.
140. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, et al. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005;103:299-306.
141. Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C Virus-associated cirrhosis. Gastroenterology 2017;153:1273-83.e1.
142. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol 2018;4:1683-90.
144. Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 2019;68:512-21.
145. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007;132:343-57.
146. Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling. Mol Cells 2009;28:49-55.
147. Williams V, Brichler S, Khan E, Chami M, Dény P, et al. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. J Viral Hepat 2012;19:744-53.
148. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000;46:420-6.
149. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012;104:790-2.
150. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol 2015;63:586-92.
151. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-38.
152. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One 2014;9:e92062.
153. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, et al; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int 2018;38:842-50.
154. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010;53:834-40.
155. Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 2005;14:329-35.
156. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardí R, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011;18:434-42.
157. Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, et al; Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol 2017;66:297-303.
159. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, et al; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31.
160. Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, et al. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol 2012;23:560-8.
161. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014;40:93-104.
162. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-9.
